SEC For		_														
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549									ISSION		OMB APPROV		DVAL
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940												MB Number: 3 stimated average burden ours per response:	
1. Name and Address of Reporting Person* Kathiresan Sekar					2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc.							Relationship on the construction of the constr	able)	ting Pers	suer Iwner	
	C/O VERVE THERAPEUTICS				3. Date of Earliest Transaction (Month/Day/Year) 08/10/2022							X Officer (give title Other (specify below) below) Chief Executive Officer				
500 TECHNOLOGY SQUARE, S (Street) CAMBRIDGE MA			02139		4. If A								up Filing (Check Applicable ne Reporting Person ore than One Reporting		on	
(City)	(S	itate)	(Zip)			Person										
		Tab	ole I - No	on-Deriv	ative s	Securities Ac	quirec	l, Di	sposed o	f, or Be	neficial	ly Owned				
Da			2. Transa Date (Month/D		ar) 2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Disposed Code (Instr. 5)			es Acquired (A) or Of (D) (Instr. 3, 4 ar		5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount	(A) or (D)	Price	Transactio			(nstr. 4)
Common Stock				08/10/	2022		М		50,000	Α	\$1.39	367,8	39	39 D		
Common Stock				08/10/2022			S ⁽¹⁾		50,000	D	\$29.9	317,8	39 I			
Common Stock												240,997		I	I I	Kathiresan Family 2021 rrevocable Frust
Common Stock											80,997		I	1 2 1	Gekar Kathiresan 1021 rrevocable Frust	
			Table II			ecurities Acq alls, warrants	,		,		-	Owned				
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date rity or Exercise (Month/Day/Year) if any			n Date,	4. Transacti Code (Ins 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	. Beneficial Ownership t (Instr. 4)

Stock Option (right to buy) Explanation of Responses:

08/10/2022

\$<mark>1.39</mark>

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.

Code v

Μ

2. The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.

50,000

(A) (D) Date Exercisable

(2)

Expiration Date

04/14/2029

Title

Common

Stock

Remarks:

/s/ Andrew Ashe, as Attorney-08/11/2022 in-Fact for Sekar Kathiresan ** Signature of Reporting Person Date

Amount or Number

of Shares

50,000

\$0.00

167,425

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.